Physician profile
Keith Rose
NPI 1871514661
$13,140.43
in general payments reported to CMS, 2019-2025
37 companies · $1,151 in 2025
The $1,151 reported for 2025 was more than what 80% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.70 · 2020: $69.95 · 2021: $211 · 2022: $681 · 2023: $10K · 2024: $980 · 2025: $1,151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,810 · Food and Beverage: $2,356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,810.08 |
| Food and Beverage | $2,355.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verathon INC. | $9,810.08 | 2023-2025 | Bronchoscope and Video Laryngoscope, Video Laryngoscope |
| Ambu INC. | $418.04 | 2022-2025 | |
| Glaxosmithkline, LLC. | $307.52 | 2022-2025 | Nucala, Trelegy Ellipta, Arexvy |
| La Jolla Pharmaceutical Company | $265.41 | 2024-2025 | Giapreza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.20 | 2020-2025 | Ofev, Jascayd |
| Shionogi INC | $241.52 | 2024 | Fetroja |
| Potrero Medical, INC. | $154.35 | 2025 | |
| Amgen INC. | $140.25 | 2022-2025 | Tezspire |
| Merck Sharp & Dohme LLC | $136.41 | 2019-2024 | Recarbrio, Zerbaxa, Dificid |
| Haemonetics Corporation | $121.21 | 2024 | Teg6s Hemostasis System |
| Astrazeneca Pharmaceuticals LP | $113.75 | 2022-2025 | Fasenra, Breztri, Andexxa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $112.46 | 2022-2023 | Lifevest |
| Mylan Specialty L.P. | $111.85 | 2022-2024 | Yupelri |
| Abiomed | $99.22 | 2023-2024 | Impella |
| United Therapeutics Corporation | $95.93 | 2021-2023 | Tyvaso |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $80.47 | 2024-2025 | Glassia |
| Philips North America LLC | $55.04 | 2020-2023 | |
| Grifols USA, LLC | $51.55 | 2022-2023 | Prolastin-C Liquid |
| Abbvie INC. | $47.84 | 2022-2023 | Teflaro |
| Mindray Ds USA, INC. | $47.49 | 2024 | Te X, Te7 Max |
| Baxter Healthcare | $47.40 | 2022 | |
| Genzyme Corporation | $46.06 | 2022-2025 | |
| Boston Scientific Corporation | $45.70 | 2022-2024 | Exalt Model D |
| Insmed, INC. | $37.05 | 2025 | Arikayce, Brinsupri |
| Getinge USA Sales, LLC | $34.70 | 2025 | Cardiohelp |
| Verona Pharma, INC. | $34.08 | 2025 | Ohtuvayre |
| Inspire Medical Systems, INC. | $33.55 | 2025 | Inspire |
| Paratek Pharmaceuticals, INC. | $29.79 | 2021 | |
| Medtronic, INC. | $26.19 | 2021 | |
| Salvin Dental Specialties, INC. | $25.00 | 2020 | |
| Advanced Respiratory, INC | $22.64 | 2021 | |
| Integra Lifesciences Corporation | $21.02 | 2023 | Codman Certas, Cusa Clarity, Codman Hakim |
| Kestra Medical Technology Services, INC. | $20.72 | 2025 | Assure Wcd |
| Viatris Specialty LLC | $18.81 | 2025 | Yupelri |
| Inquis Medical, INC. | $18.13 | 2024 | |
| Pfizer INC. | $15.00 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.